Business
Jaguar Health Subsidiary Napo Pharmaceuticals Appoints Brian Sutton National Business Director
SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company
About this update from Jaguar Health, Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company’s wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), has promoted Brian Sutton to the role of national business director for Napo.“From a sales strategy perspective, our core focus at Napo is now on what we call ‘super targets’. Approximately 72% of our top Mytesi® prescribers are primary care providers - family practitioners, general practitioners, internal medicine doctors, nurse practitioners and physician assistants - and this segment has contributed to grow,” Sutton commented. “My mandate as the new head of Napo’s sales force is to help our team significantly expand our focus on these existing prescribers while also adding new targets within these same specialties. Additionally, from a marketing standpoint, we believe this refined sales strategy complements the ongoing social media initiatives we’ve implemented to help drive efficient patient mobilization.”Sutton previously served as western regional business director for Napo. Prior to joining Napo, he was an executive cardiovascular hospital account manager with Novartis, an executive institutional business manager with Bristol-Myers Squib in HIV, and an institutional diabetes account manager with Novo Nordisk A/S, and held roles with Shire, Johnson & Johnson and other companies in the pharmaceutical and medical device industries. He has a B.S. in Marketing from Penn State University and an M.S. in Information Systems Engineering from the CHUBB Institute.\"We are very happy to have appointed Brian to this key role,” Lisa Conte, Jaguar’s president and CEO, stated. “We believe his broad sales, marketing, and analytical expertise in the pharmaceutical industry, and in the HIV sector at Napo, will play a significant role as we continue to focus on expanding sales of our Mytesi drug product for its FDA-approved indication by leveraging efficient tactics based on our empirical experience, and as we continue efforts to develop potential follow-on indications to make Mytesi available to all patients in need as a successful, first-in-class entry to gastrointestinal care....